Core B: Vector Core. This Vector Core will provide high quality preparations of viral and plasmid vectors to facilitate research involving the development of therapeutic strategies in both small and large animal models. Services offered by the Core include providing consulting, reagents and training related to vector production. This includes production of vectors and muscular dystrophy related reagents (cell lines, vector backbones, protocols, antibodies etc.) for members of this Center as well as laboratories in the US and across the World to support their efforts related to gene therapy for the muscular dystrophies. The Vector Core will be directed by Dr. Jeff Chamberlain with assistance from Dr. James Allen. Dr. Allen, in conjunction with the Chamberlain lab has established protocols for the production of adeno-associated viral vectors, particularly AAV6 but also several other pseudotyped vectors including AAVS and 9, and lentiviral vectors. For many years such vectors and associated reagents have been supplied by us to laboratories around the world as part of collaborations, and for a recent 5 year period these reagents were provided via our Wellstone Center Vector Core lab. We also have numerous dystrophin and utrophin cDNAs and antibodies that will be made available via this Core lab. We will provide high quality, high titer preparations of adeno-associated viral (AAV) vectors based primarily on AAV serotype 6, but also for AAV 1, 8, 9 and emerging new and modified serotypes. These recombinant AAV (rAAV) vectors will be provided to members of the Wellstone Center using funds from this Core, and to other muscular dystrophy researchers on a recharge basis to cover costs. We also have numerous dystrophin cDNAs and antibodies that will be made available via this Core lab. Training will allow investigators to apply methods for production and purification of viral vectors (AAV and lentiviral) in their own labs as desired. Consulting will be available to guide the use of the AAV and lentiviral vectors. Finally, we will provide reagents (such as vector backbones, plasmids, antibodies and protocols) that have been developed by the Chamberlain group or members of this Wellstone Center to National groups studying muscular dystrophy.

Public Health Relevance

This Core represents an important vector resource, as production uses highly specialized techniques not available to most labs. Gene therapy is an important technique for a variety of muscular dystrophies, including DMD and FSHD. AAV vectors are useful for gene replacement as well as gene knockdown. Lentiviral vectors are an important tool for modifying stem cells and studying disease mechanisms. However the cost and human resources needed to bring production into a lab are considerable

National Institute of Health (NIH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZAR1-KM (M1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Washington
United States
Zip Code
Lawlor, Michael W; Beggs, Alan H; Buj-Bello, Ana et al. (2016) Skeletal Muscle Pathology in X-Linked Myotubular Myopathy: Review With Cross-Species Comparisons. J Neuropathol Exp Neurol 75:102-10
Bengtsson, Niclas E; Seto, Jane T; Hall, John K et al. (2016) Progress and prospects of gene therapy clinical trials for the muscular dystrophies. Hum Mol Genet 25:R9-17
Kolwicz Jr, Stephen C; Odom, Guy L; Nowakowski, Sarah G et al. (2016) AAV6-mediated Cardiac-specific Overexpression of Ribonucleotide Reductase Enhances Myocardial Contractility. Mol Ther 24:240-50
Su, Wei; Kang, John; Sopher, Bryce et al. (2016) Recombinant adeno-associated viral (rAAV) vectors mediate efficient gene transduction in cultured neonatal and adult microglia. J Neurochem 136 Suppl 1:49-62
Macadangdang, Jesse; Guan, Xuan; Smith, Alec S T et al. (2015) Nanopatterned Human iPSC-based Model of a Dystrophin-Null Cardiomyopathic Phenotype. Cell Mol Bioeng 8:320-332
Ramos, Julian; Chamberlain, Jeffrey S (2015) Gene Therapy for Duchenne muscular dystrophy. Expert Opin Orphan Drugs 3:1255-1266
Bisset, Darren R; Stepniak-Konieczna, Ewa A; Zavaljevski, Maja et al. (2015) Therapeutic impact of systemic AAV-mediated RNA interference in a mouse model of myotonic dystrophy. Hum Mol Genet 24:4971-83
Guan, Xuan; Wang, Zejing; Czerniecki, Stefan et al. (2015) Use of Adeno-Associated Virus to Enrich Cardiomyocytes Derived from Human Stem Cells. Hum Gene Ther Clin Dev 26:194-201
Hollinger, Katrin; Chamberlain, Jeffrey S (2015) Viral vector-mediated gene therapies. Curr Opin Neurol 28:522-7
Cheever, Thomas R; Berkley, Dale; Braun, Serge et al. (2015) Perspectives on best practices for gene therapy programs. Hum Gene Ther 26:127-33

Showing the most recent 10 out of 11 publications